Spatial transcriptomics reveals distinct tumor microenvironment of murine breast cancer model undergoing treatment with a humanized monoclonal antibody targeting FABP4

Circulating levels of adipocyte fatty acid binding protein (A-FABP, also known as FABP4) are linked with metabolic dysregulation. Our previous study demonstrated that high serum levels of FABP4 increased the risk of obesity associated breast cancer. The treatment with anti-FABP4 monoclonal anitbody was demonstrated to inhibit mammary tumor growth in a syngeneic mouse model. We hypothesized that spatial transcriptomic analysis would identidy the relationship between tumor cells and tumor-associated stromal cells during the antibody treatment. Two pairs of primary tumors from both antibody treatment group and PBS control group were collected for sample preperation and analysis according to the manufacture’s introduction.